Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2019 Aug 20;516(2):373-380. doi: 10.1016/j.bbrc.2019.06.033. Epub 2019 Jun 15.

Therapeutic impact of orally administered cannabinoid oil extracts in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis.

Author information

1
College of Pharmacy, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada; Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, R3E 0W2, Canada; Chongqing General Hospital, Chongqing, 40000, China.
2
College of Pharmacy, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada.
3
College of Pharmacy, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Safat, 13110, Kuwait. Electronic address: samaa.alrushaid@hsc.edu.kw.
4
College of Medicine, University of Manitoba, Winnipeg, MB, R3E 3P5, Canada.
5
Department of Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, MB, R3E 0Z3, Canada.
6
Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, R3E 0W2, Canada.
7
College of Pharmacy, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada; Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, R3E 0W2, Canada; College of Rehabilitation Medicine, Health Sciences Centre, Winnipeg, MB, R3A 1R9, Canada; College of Medicine, University of Manitoba, Winnipeg, MB, R3E 3P5, Canada; Department of Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, MB, R3E 0Z3, Canada. Electronic address: mikemamakams@gmail.com.

Abstract

There is a growing surge of investigative research involving the beneficial use of cannabinoids as novel interventional alternatives for multiple sclerosis (MS) and associated neuropathic pain (NPP). Using an experimental autoimmune encephalomyelitis (EAE) animal model of MS, we demonstrate the therapeutic effectiveness of two cannabinoid oil extract formulations (10:10 & 1:20 - tetrahydrocannabinol/cannabidiol) treatment. Our research findings confirm that cannabinoid treatment produces significant improvements in neurological disability scoring and behavioral assessments of NPP that directly result from their ability to reduce tumor necrosis factor alpha (TNF-α) production and enhance brain derived neurotrophic factor (BDNF) production. Henceforth, this research represents a critical step in advancing the literature by scientifically validating the merit for medical cannabinoid use and sets the foundation for future clinical trials.

KEYWORDS:

BDNF; Cannabinoid oil extracts; Multiple sclerosis; Neurological disability; Neuropathic pain; TNF-α

PMID:
31213295
DOI:
10.1016/j.bbrc.2019.06.033

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center